

Victor Ho Fun Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5403127/publications.pdf>

Version: 2024-02-01

164
papers

4,648
citations

109264

35
h-index

123376

61
g-index

166
all docs

166
docs citations

166
times ranked

6885
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. <i>Nature Genetics</i> , 2012, 44, 1330-1335.	9.4	286
2	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2013, 14, 777-786.	5.1	280
3	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , 2018, 77, 16-21.	0.8	189
4	MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. <i>Carcinogenesis</i> , 2013, 34, 454-463.	1.3	181
5	Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1116-1125.	0.4	159
6	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
7	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3091-3100.	0.8	147
8	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11283-11288.	3.3	144
9	Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 138-145.	0.4	117
10	Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 121-129.	1.8	116
11	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. <i>Nature Communications</i> , 2018, 9, 4663.	5.8	106
12	Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1148-1155.	0.5	97
13	Molecular subtyping of cancer: current status and moving toward clinical applications. <i>Briefings in Bioinformatics</i> , 2019, 20, 572-584.	3.2	91
14	Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. <i>Nature Communications</i> , 2021, 12, 1540.	5.8	88
15	The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. <i>International Journal of Cancer</i> , 2019, 144, 1713-1722.	2.3	82
16	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. <i>International Journal of Cancer</i> , 2015, 137, 311-319.	2.3	72
17	Whole-exome sequencing identifies <i>MST1R</i> as a genetic susceptibility gene in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3317-3322.	3.3	71
18	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017, 123, 4147-4157.	2.0	70

#	ARTICLE	IF	CITATIONS
19	Intravoxel incoherent motion MR imaging: comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis. <i>European Radiology</i> , 2013, 23, 2793-2801.	2.3	62
20	Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis. <i>Head & Neck Oncology</i> , 2009, 1, 13.	2.3	54
21	Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0157969.	1.1	54
22	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. <i>Human Molecular Genetics</i> , 2016, 26, ddw414.	1.4	50
23	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. <i>Human Molecular Genetics</i> , 2016, 25, 620-629.	1.4	50
24	Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging. <i>European Radiology</i> , 2014, 24, 176-183.	2.3	49
25	Sarcopenia and mortality in cancer: A meta-analysis. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S28-S33.	0.7	49
26	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2021, 153, 109-122.	1.3	48
27	Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells. <i>Gastroenterology</i> , 2015, 149, 1825-1836.e5.	0.6	46
28	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	2.0	43
29	Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. <i>Hepatology</i> , 2021, 74, 2580-2594.	3.6	43
30	Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. <i>Oncolimmunology</i> , 2017, 6, e1273311.	2.1	41
31	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018, 126, 1-8.	0.9	40
32	Dosimetric Predictors of Radiation-induced Acute Nausea and Vomiting in IMRT for Nasopharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 176-182.	0.4	39
33	Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma – How far have we achieved?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 13-23.	2.0	39
34	Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 5292-5308.	0.8	39
35	Psychometric assessment of the Chinese version of the brief illness perception questionnaire in breast cancer survivors. <i>PLoS ONE</i> , 2017, 12, e0174093.	1.1	38
36	Phase II, Randomized Study of Spaltalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6413-6423.	3.2	37

#	ARTICLE	IF	CITATIONS
37	Novel therapy for nasopharyngeal carcinoma – Where are we. <i>Oral Oncology</i> , 2014, 50, 798-801.	0.8	36
38	Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. <i>Clinical Oncology</i> , 2016, 28, e52-e60.	0.6	36
39	Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 880-888.	0.6	35
40	Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. <i>Scientific Reports</i> , 2013, 3, 2855.	1.6	34
41	Metastasis-suppressing <i>NID2</i> , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 78859-78871.	0.8	33
42	EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib. <i>BMC Bioinformatics</i> , 2015, 16, 85.	1.2	32
43	Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. <i>Future Oncology</i> , 2017, 13, 603-613.	1.1	31
44	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. <i>Scientific Reports</i> , 2017, 7, 6595.	1.6	29
45	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9077-9077.	0.8	29
46	Intravoxel water diffusion heterogeneity MR imaging of nasopharyngeal carcinoma using stretched exponential diffusion model. <i>European Radiology</i> , 2015, 25, 1708-1713.	2.3	28
47	Metabolic Phenotype of Stage IV Lung Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e190-e195.	0.7	28
48	Illness perceptions among cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 1295-1304.	1.0	28
49	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT – A study by the HKNPCSG. <i>Head and Neck</i> , 2019, 41, 3661-3669.	0.9	28
50	Sarcopenia and mortality in different clinical conditions: A meta-analysis. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S19-S27.	0.7	28
51	Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. <i>Oncogene</i> , 2019, 38, 3119-3133.	2.6	25
52	Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. <i>BMC Cancer</i> , 2011, 11, 288.	1.1	24
53	Can Intensity-Modulated Radiotherapy Preserve Oral Health-Related Quality of Life of Nasopharyngeal Carcinoma Patients?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e213-e221.	0.4	24
54	Cervical nodal volume for prognostication and risk stratification of patients with nasopharyngeal carcinoma, and implications on the TNM-staging system. <i>Scientific Reports</i> , 2017, 7, 10387.	1.6	24

#	ARTICLE	IF	CITATIONS
55	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 40-54.	4.2	24
56	Virtual Contrast-Enhanced Magnetic Resonance Images Synthesis for Patients With Nasopharyngeal Carcinoma Using Multimodality-Guided Synergistic Neural Network. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1033-1044.	0.4	24
57	Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1078-1086.	0.4	23
58	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. <i>Surgical Oncology</i> , 2019, 28, 228-235.	0.8	23
59	Comparing dyadic cognitive behavioral therapy (CBT) with dyadic integrative body-mind-spirit intervention (I-BMS) for Chinese family caregivers of lung cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2020, 28, 1523-1533.	1.0	23
60	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. <i>Radiotherapy and Oncology</i> , 2020, 148, 73-81.	0.3	23
61	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. <i>PLoS ONE</i> , 2015, 10, e0128360.	1.1	23
62	Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1067-1078.	0.8	21
63	Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. <i>BMC Bioinformatics</i> , 2018, 19, 88.	1.2	20
64	Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. <i>British Journal of Cancer</i> , 2019, 121, 690-698.	2.9	19
65	Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors. <i>Cancer Control</i> , 2021, 28, 107327482110297.	0.7	18
66	A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening. <i>Frontiers in Oncology</i> , 2018, 8, 279.	1.3	17
67	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. <i>Communications Biology</i> , 2020, 3, 759.	2.0	17
68	Electroacupuncture trigeminal nerve stimulation plus body acupuncture for chemotherapy-induced cognitive impairment in breast cancer patients: An assessor-participant blinded, randomized controlled trial. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 88-96.	2.0	17
69	Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. <i>Hong Kong Medical Journal</i> , 2014, 20, 178-86.	0.1	17
70	Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9007-9007.	0.8	17
71	PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2016, 37, 320-332.	1.3	16
72	Illness perceptions as predictors of psychological distress among head and neck cancer survivors: a longitudinal study. <i>Head and Neck</i> , 2018, 40, 2362-2371.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma. <i>Angiogenesis</i> , 2022, 25, 181-203.	3.7	15
74	Extracapsular lymph node spread in recurrent nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2011, 121, 2576-2580.	1.1	14
75	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 114-125.	2.9	14
76	The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. <i>Postgraduate Medical Journal</i> , 2017, 93, 395-400.	0.9	13
77	Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985999.	1.4	13
78	Different definitions of sarcopenia and mortality in cancer: A meta-analysis. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S34-S38.	0.7	13
79	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6002-6002.	0.8	13
80	Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. <i>BMC Cancer</i> , 2016, 16, 147.	1.1	12
81	Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis. <i>BMC Cancer</i> , 2018, 18, 776.	1.1	12
82	Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery. <i>BMC Cancer</i> , 2009, 9, 131.	1.1	11
83	Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties. <i>Computers in Biology and Medicine</i> , 2015, 63, 293-300.	3.9	11
84	Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 355-362.	0.6	11
85	Intravoxel incoherent motion MR imaging in nasopharyngeal carcinoma: comparison and correlation with dynamic contrast enhanced MR imaging. <i>Oncotarget</i> , 2017, 8, 68472-68482.	0.8	11
86	Dose volume effects of re-irradiation for locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 180-187.	0.9	11
87	Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1417.	1.3	11
88	SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes. <i>Cancers</i> , 2022, 14, 3285.	1.7	11
89	Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves's ophthalmopathy treated with retro-orbital irradiation. <i>Radiation Oncology</i> , 2012, 7, 199.	1.2	10
90	Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. <i>Oncology Letters</i> , 2013, 5, 637-640.	0.8	10

#	ARTICLE	IF	CITATIONS
91	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	0.6	10
92	The effect of different measurement modalities in the association of lean mass with mortality: A systematic review and meta-analysis. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S13-S18.	0.7	10
93	Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 3457.	1.0	9
94	Treatment outcomes of postradiation second head and neck malignancies managed by a multidisciplinary approach. <i>Head and Neck</i> , 2015, 37, 815-822.	0.9	9
95	Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma. <i>Clinical Oncology</i> , 2016, 28, 42-49.	0.6	9
96	Study protocol of a randomized controlled trial comparing integrative bodyâ€“mindâ€“spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. <i>Journal of Evidence-informed Social Work</i> , 2018, 15, 258-276.	0.8	9
97	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Chinese. <i>International Journal of Cancer</i> , 2018, 143, 2289-2298.	2.3	9
98	The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626145.	1.3	9
99	Systematic review and meta-analysis of lean mass and mortality: Rationale and study description. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S3-S12.	0.7	9
100	A Multi-Center Study of CT-Based Neck Nodal Radiomics for Predicting an Adaptive Radiotherapy Trigger of Ill-Fitted Thermoplastic Masks in Patients with Nasopharyngeal Carcinoma. <i>Life</i> , 2022, 12, 241.	1.1	9
101	Return to Work and Work Productivity During the First Year After Cancer Treatment. <i>Frontiers in Psychology</i> , 2022, 13, 866346.	1.1	9
102	Antifungal susceptibility and phenotypic characterization of oral isolates of a black fungus from a nasopharyngeal carcinoma patient under radiotherapy. <i>BMC Oral Health</i> , 2015, 15, 39.	0.8	8
103	Integrative Palliative Cancer Care in Hong Kong: An Overview and an Example from the East. <i>Clinical Oncology</i> , 2019, 31, 589-594.	0.6	7
104	Radiation Therapy for Thoracic Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 109-125.	0.9	7
105	Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. <i>Oral Oncology</i> , 2021, 114, 105158.	0.8	7
106	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2157.	1.7	7
107	Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study. <i>Journal of Hematology and Oncology</i> , 2022, 15, 66.	6.9	7
108	Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. <i>Molecular BioSystems</i> , 2016, 12, 1552-1563.	2.9	6

#	ARTICLE	IF	CITATIONS
109	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. <i>Clinical Oncology</i> , 2019, 31, 560-569.	0.6	6
110	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2020, 32, e1-e9.	0.6	6
111	Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 651299.	1.3	6
112	Afatinib in EGFR TKI-Na ⁺ ve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , 2021, 11, 709877.	1.3	6
113	Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. <i>Journal of Cancer</i> , 2021, 12, 4585-4594.	1.2	6
114	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na ⁺ ve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	1.7	6
115	The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. <i>Advances in Therapy</i> , 2022, 39, 2379-2397.	1.3	6
116	Natural course and tumor doubling time of nasopharyngeal carcinoma. A study of 15 patients. <i>Oral Oncology</i> , 2011, 47, 742-746.	0.8	5
117	Prediction of anti-EGFR drug resistance base on binding free energy and hydrogen bond analysis. , 2013, , .		5
118	Personnel dose reduction in ⁹⁰ Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward. <i>British Journal of Radiology</i> , 2017, 90, 20160591.	1.0	5
119	Metronomic oral cyclophosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6518.	0.4	5
120	Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. <i>Ophthalmology and Therapy</i> , 2021, 10, 5-12.	1.0	5
121	Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 1148.	1.3	5
122	East Meets West: Convergence of the Art and Science of Oncology. <i>Clinical Oncology</i> , 2019, 31, 487-489.	0.6	4
123	The Relationships Between Radiation Dosage and Long-term Swallowing Kinematics and Timing in Nasopharyngeal Carcinoma Survivors. <i>Dysphagia</i> , 2022, 37, 612-621.	1.0	4
124	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5511-5511.	0.8	4
125	Analysis of the Relative Movements Between EGFR and Drug Inhibitors Based on Molecular Dynamics Simulation. <i>Current Bioinformatics</i> , 2018, 13, 299-309.	0.7	4
126	Refining TNM-8M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2022, 126, 105736.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 247.	0.4	3
128	Oncology Healthcare Provision in Hong Kong: Viewpoint of a Clinical Oncologist. <i>Clinical Oncology</i> , 2019, 31, 490-491.	0.6	3
129	Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100322.	0.6	3
130	Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4647.	1.8	3
131	Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 4-6.	0.7	2
132	Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East. <i>Clinical Oncology</i> , 2019, 31, 549-559.	0.6	2
133	Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong—a Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. <i>Cancer Control</i> , 2021, 28, 107327482110471.	0.7	2
134	Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 6065-6065.	0.8	2
135	Phase II study of consolidative intensity-modulated radiation therapy following first-line palliative systemic chemotherapy for de novo previously untreated metastatic (M1) nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 6524-6524.	0.8	2
136	Evaluation of Multisource Adaptive MRI Fusion for Gross Tumor Volume Delineation of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 816678.	1.3	2
137	Standard of Care for Nasopharyngeal Carcinoma (2018–2020). , 2019, , 205-238.		1
138	Cancer Immunotherapy for Nasopharyngeal Carcinoma. , 2019, , 337-351.		1
139	Serial early post-IMRT undetectable plasma EBV DNA to predict outcomes in non-metastatic nasopharyngeal cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 6007-6007.	0.8	1
140	The aftermath of LUX-Lung 7 study—what have we learnt from it?. <i>Annals of Translational Medicine</i> , 2016, 4, 294-294.	0.7	1
141	Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. <i>South Asian Journal of Cancer</i> , 2014, 03, 175-178.	0.2	1
142	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. <i>Cancers</i> , 2022, 14, 1923.	1.7	1
143	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. <i>Frontiers in Oncology</i> , 2022, 12, 842281.	1.3	1
144	Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 3362.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Impact of intravenous contrast used in computed tomography on radiation dose to carotid arteries and thyroid in intensity-modulated radiation therapy planning for nasopharyngeal carcinoma. <i>Medical Dosimetry</i> , 2017, 42, 137-144.	0.4	0
146	Palliative Care for Chest Tumors – Hong Kong, France and Canada. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 167-180.	0.2	0
147	End of Life Issues – Hong Kong, France and Canada. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 181-194.	0.2	0
148	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 120-136.	0.2	0
149	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?. <i>Lancet Oncology</i> , 2019, 20, e66.	5.1	0
150	Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6046-6046.	0.8	0
151	A potential survival impact of blood immune cells in patients with locoregionally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18027-e18027.	0.8	0
152	The Tim3-galectin-9 interactions in the tumor microenvironment of nasopharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2629-2629.	0.8	0
153	Editorial: Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 698515.	1.3	0
154	Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14530-e14530.	0.8	0
155	A Computational Study of Three Frequent Mutations of EGFR and their Effects on Protein Dimer Formation and Non-Small Cell Lung Cancer Drug Resistance. <i>Current Bioinformatics</i> , 2016, 11, 382-391.	0.7	0
156	How far have we achieved by systemic therapy for recurrent/metastatic nasopharyngeal carcinoma?. <i>Translational Cancer Research</i> , 2016, 5, S1424-S1427.	0.4	0
157	Prognostic factors for oligometastasis after 1 st line first or second generation TKI for EGFR-mutated metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20521-e20521.	0.8	0
158	New hope for advanced nasopharyngeal cancer – an Epstein-Barr virus-driven endemic malignancy?. <i>Translational Cancer Research</i> , 2018, 7, S53-S57.	0.4	0
159	Excessive mortality in 1,353 five-year survivors of nasopharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24090-e24090.	0.8	0
160	Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18519-e18519.	0.8	0
161	Reply. <i>Hepatology</i> , 2022, 75, 1346-1346.	3.6	0
162	Real-World Perspectives From Surgeons and Oncologists on Resectability Definition and Multidisciplinary Team Discussion of Stage III NSCLC in People’s Republic of China, Hong Kong, and Macau: A Physician Survey. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100308.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Overall survival benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer harboring L858R mutation: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, e21064-e21064.	0.8	0
164	Isoflavonoid-based therapeutics to remodel immunologically cold tumors in nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2022, 40, e14534-e14534.	0.8	0